港股異動 | 威高股份(1066.HK)續漲近5%再次破頂 3日累計大漲18%
格隆匯6月2日丨威高股份(1066.HK)續漲4.87%,報14.64港元,暫成交9016萬港元,最新總市值662.1億港元。公司股價自高位回落後,近日再起升勢,3日累計大漲近18%再次創下新高。光大證券曾指出,疫情短期影響部分擇期手術延後,但需求仍然存在,預計骨科2020年仍有望維持快速增長。此外,公司成功收購位於英國的經銷商,加快佈局歐洲市場。值得一提的是,公司擬於7月22日股東周年大會上提呈一項特別決議案,授予董事購回總面值不超過該決議案獲通過當日的已發行H股總面值10%的已發行H股的購回授權。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.